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Abstract 39 
Introduction: Epidemiology has linked preeclampsia (PET) to decreased maternal serum 25-40 
hydroxyvitamin D3 (25(OH)D3). However, alterations in systemic and placental/decidual 41 
transport and metabolism of 25(OH)D3 during pregnancy suggest that other forms of vitamin D 42 
may also contribute to the pathophysiology of PET.  43 
 44 
Methods: In a cross sectional analysis of normal pregnant women at 1st (n=25) and 3rd 45 
trimester (n=21), pregnant women with PET (n=22), and non-pregnant female controls (n=20) 46 
vitamin D metabolites were quantified in paired maternal serum, placental, and decidual tissue.  47 
 48 
Results: Serum 25(OH)D3 was not significantly different in sera across all four groups. In 49 
normal 3rd trimester pregnant women serum active 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 50 
was significantly higher than non-pregnant, normal 1st trimester pregnant, and PET women. 51 
Conversely, PET sera showed highest levels of the catabolites 3-epi-25(OH)D3 and 24,25-52 
dihydroxyvitamin D3 (24,25(OH)2D3).  Serum albumin was significantly lower in normal 3rd 53 
trimester pregnant women and PET relative to normal 1st trimester pregnant women, but there 54 
was no change in free/bioavailable 25(OH)D3. In PET placental tissue, 25(OH)D3 and 3-epi-55 
25(OH)D3 were lower than normal 3rd trimester tissue, whilst placental 24,25(OH)2D3 was 56 
highest in PET. Tissue 1,25(OH)2D3 was detectable in 1st trimester decidua, which also showed 57 
10-fold higher 25(OH)D3 relative to paired placentae. 3-epi-25(OH)D3 and 24,25(OH)2D3 were 58 
not different for decidua and placenta. In normal 3rd trimester pregnant women, total, free and 59 
bioavailable maternal 25(OH)D3 correlated with placental 25(OH)D3, but this was not 60 
conserved for PET.  61 
 62 
Discussion: These data indicate that PET is associated with decreased activation, increased 63 
catabolism, and impaired placental uptake of 25(OH)D3. 64 
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Introduction 1 
Human pregnancy is associated with important changes in vitamin D physiology. Maternal 2 
circulating concentrations of the active form of vitamin D, 1,25-dihydroxyvitamin D3 3 
(1,25(OH)2D3), increase significantly during early gestation [1]. This appears to be due to 4 
increased renal activity of the enzyme 25-hydroxyvitamin D-1α-hydroxylase (1α-hydroxylase), 5 
which converts inactive 25-hydroxyvitamin D (25(OH)D3) to 1,25(OH)2D3  [2]. 1α-hydroxylase 6 
expression and activity has also been described in human decidua and fetal trophoblast [3-5]. 7 
Placental 1α-hydroxylase does not appear to make a major contribution to the elevated 8 
maternal 1,25(OH)2D3 associated with pregnancy [2]. Instead co-expression of the nuclear 9 
vitamin D receptor (VDR) in maternal and fetal placental tissues suggests a more localised role 10 
for 1,25(OH)2D3. Albeit less well understood, recent studies suggest this extends far beyond the 11 
known classical calciotropic effects of vitamin D, and includes key roles in normal decidual 12 
immune function and placental implantation [6-9] 13 
 14 
Vitamin D-insufficiency is prevalent in pregnant women [10, 11]. Maternal 25(OH)D is the 15 
principal determinant of neonatal circulating 25(OH)D3, thus infants of vitamin D–deficient 16 
mothers are also at risk of vitamin D-deficiency [12].  Maternal 25(OH)D3-deficiency has also 17 
been linked to adverse pregnancy outcomes associated with malplacentation, including 18 
preeclampsia (PET), small-for-gestational age and preterm birth [13-17]. Mothers receiving 19 
vitamin D supplementation from early pregnancy (two trials, 219 women) have been reported to 20 
have a lower risk of PET and a positive association between serum 25(OH)D3 and reduced 21 
PET risk has been reported [18]. A recent systematic review and meta-analysis, which included 22 
11 observational studies, found a significant inverse relationship between maternal 25(OH)D3 23 
and risk of PET in 5 of the studies. Meta-analyses similarly suggested an inverse relationship 24 
between maternal 25(OH)D3 and PET risk, but could not infer causality due to the insufficient 25 
quality of evidence [19, 20]. 26 
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 27 
This heterogeneity of data for vitamin D and PET in part reflects our limited understanding of the 28 
effects of vitamin D during pregnancy. Moreover, almost all studies to date have relied on 29 
maternal serum concentrations of 25(OH)D3 as the determinant of vitamin D status and 30 
function, despite the potential importance of other vitamin D metabolites such as 1,25(OH)2D3 31 
[21], 3-epi-25(OH)D3 [22], and 24-hydroxylated vitamin D metabolites (24,25(OH)2D3) [23]. 32 
Furthermore, placental expression of 1α-hydroxylase suggests that tissue-specific 33 
concentrations of 25(OH)D3 and other vitamin D metabolites are likely to be potential 34 
determinants of local vitamin D function across gestation [6]. Finally, vitamin D binding protein 35 
(DBP) and albumin are known to act as serum transporters of vitamin D metabolites, but also 36 
define tissue bioavailability and function by modulating the balance of bound and free forms of 37 
vitamin D [24]. The aim of the current study was therefore to characterise the relative impact of 38 
each of these facets of vitamin D metabolism and transport on normal and PET pregnancies. 39 
 40 
Materials and Methods 41 
Ethical approval 42 
Written informed consent was obtained from all women recruited into the study. Matched human 43 
sera, placenta and decidua samples were collected with the approval of Health Research 44 
Authority - West Midlands, Edgbaston Research Ethics Committee (NHS REC 06/Q2707/12 45 
[2006 approval]) (RG_14-194 [10.2014 approval]). 46 
 47 
Sample collection 48 
All samples were obtained from women in the West Midlands area of the UK (n=88). Patient 49 
demographics and baseline clinical data are summarised in Supplemental Table 1. 50 
Importantly, no significant difference in maternal age or BMI was measured. As anticipated, in 51 
the PET group mean arterial blood pressure was significantly raised (p<0.0001) and fetal 52 
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birthweight reduced (p<0.01) comparative to NP3. There was however no significant difference 53 
in gestational age at delivery. 1st trimester sera, placental and decidual samples were obtained 54 
from women with uncomplicated pregnancies undergoing surgical termination of pregnancy 55 
between 8-13 weeks gestation (n=25), as determined by ultrasound measurement of crown 56 
rump length (Walsall Manor NHS Trust).  57 
 58 
Normal uncomplicated 3rd trimester (>37 weeks) (n=21) and PET (>34 weeks) (n=22) sera and 59 
placental samples were collected from pregnant women consented prior to delivery at 60 
Birmingham Women’s Foundation Hospital Trust (BWFHT). All PET cases were prospectively 61 
diagnosed according to current International definitions (ISSHP, 2014)[25]; new hypertension 62 
presenting after 20 weeks, with one or more of the following new onset conditions: 1. proteinuria 63 
(urinary protein: creatinine ratio > 30 mg/mmol or a validated 24-hour urine collection > 300 mg 64 
protein); 2. other maternal organ dysfunction (renal insufficiency, liver involvement, neurological 65 
and/ or haematological complications); 3. utero-placental dysfunction (fetal growth restriction). 66 
PET severity was categorised as; mild - diastolic ≥ 90–99 mmHg, systolic ≥140–149 mmHg 67 
(n=9), moderate - diastolic ≥ 100–109 mmHg (n=7), systolic ≥150–159 mmHg, severe - diastolic 68 
≥ 110 mmHg, systolic ≥160 mmHg (n=6). Maternal mean arterial blood pressure (MABP) was 69 
significantly elevated comparative to the normal pregnant control group. A healthy non-pregnant 70 
female ‘control’ group (n=20) was also recruited. 71 
 72 
Sample preparation for LC-MS/MS Analysis 73 
Placental biopsies (approximately 1g weight) were defrosted on ice and homogenised in 700µl 74 
ice-cold PBS using a gentle MACS tissue dissociator (Miltenyi Biotec, Woking, UK,) with M 75 
tubes using pre-set programs developed for total RNA or mRNA isolation from fresh or frozen 76 
samples. Homogenates were centrifuged at 10,000g for 5 minutes and the clear homogenate 77 
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was transferred to a separate Eppendorf tube. Total protein content in the homogenate was 78 
immediately measured (ThermoFisher, Waltham, MA, USA). 79 
   80 
Extraction of serum and tissues samples for LC-MS/MS analysis 81 
Vitamin D metabolites were extracted from donor serum (0.2 mL) or placental tissue 82 
homogenates as described previously [26]. Resulting samples were reconstituted in 125 µL 83 
water/methanol (50/50%) for LC-MS/MS analysis as previously described [26] using a Waters 84 
ACQUITY ultra performance liquid chromatography [uPLC] coupled to a Waters Xevo TQ-S 85 
mass spectrometer [Waters, Manchester, UK]). Analysis was carried out in multiple reaction 86 
monitoring (MRM) mode, with optimised MRM transitions for each analyte as described 87 
previously [26]. External quality control (QC) samples (LGC Standards, Teddington, UK) for 88 
25(OH)D3 and 25(OH)D2 were used to assess accuracy and precision within batch runs. QCs 89 
across different concentration ranges to determine inter- and intra- day accuracy and precision 90 
for each analyte were as described previously [26]. Data analysis was performed with Waters 91 
Target Lynx.  92 
 93 
Analysis of DBP and albumin and estimation of free vitamin D metabolites  94 
Human vitamin D binding protein (DBP) (R&D Biosystems, Abingdon, UK), and human albumin 95 
(Abcam, Cambridge, UK) were measured using ELISA analyses as per manufacturer’s 96 
instructions. Serum concentrations of free (total minus DBP and albumin-bound) and 97 
bioavailable (total minus DBP bound) serum 25(OH)D3 were calculated based on total 98 
25(OH)D3 and DBP/albumin values using equations described previously [27]. 99 
 100 
Statistics 101 
Unless otherwise stated, data are shown as median values with interquartile ranges (IQR). All 102 
statistical analyses were carried out using GraphPad PRISM Version 6.07 software (San Diego, 103 
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CA, USA). Normality was assessed using D’Agostino-Pearson omnibus normality test, with 104 
Student’s t-test (parametric), or Mann-Whitney (non-parametric) test utilised to compare two 105 
data sets. Multifactorial data were compared using either one-way ANOVA (parametric) or 106 
Kruskal-Wallis test (non-parametric) based on ranks, with Tukey or Dunn’s method used for 107 
post hoc multiple-comparison procedures. 108 
 109 
Results 110 
Dysregulation of serum vitamin D metabolism in PET 111 
Four serum vitamin D metabolites were consistently quantifiable in both pregnant and non-112 
pregnant women; 25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3, 3-epi-25(OH)D3.  In non-pregnant 113 
women 25(OH)D3 concentrations (median 33.4, IQR 20.8–44.3 nmol/L), were similar to healthy 114 
1st trimester (NP1, 28.8, 20.3–46.9nmol/L) and 3rd trimester (NP3, 45.2, 32.5–59.2nmol/L) 115 
pregnancies, as well as women diagnosed with PET (35.3, 17.7–54.7 nmol/L) (Figure 1A). By 116 
contrast, serum 1,25(OH)2D3 concentrations in non-pregnant women (34.2, 29.3–55.0 pmol/L), 117 
were significantly lower than in pregnant women, including NP1 (113.7, 82.7–198.3 pmol/L, 118 
p<0.0001), NP3 (254.7, 195.7–310.1 pmol/L, P<0.0001), and PET (171.2, 113.0–236.3 pmol/L, 119 
p<0.0001) groups (Figure 1B). Consistent with previous studies [28], NP3 levels of 120 
1,25(OH)2D3 were more than two-fold higher than NP1 (p<0.0001), and significantly lower 121 
concentrations of 1,25(OH)2D3 (p<0.01) were observed in the PET cohort compared to NP3 122 
(Figure 1B). Linear regression analysis confirmed gestational age was not a significant 123 
determinant of any serum vitamin D metabolite (data not shown).  124 
 125 
Serum concentrations of 24,25(OH)2D3 in non-pregnant women (3.3, 1.6–4.7 nmol/L) were 126 
higher than NP1 (1.8, 0.8-3.7 nmol/L), but lower than NP3 (7.6, 5.6-10.0 nmol/L, p<0.05) and 127 
PET (10.9, 7.3-22.5 nmol/L, p<0.001) (Figure 1C). Both NP3 and PET samples showed 128 
significantly higher 24,25(OH)2D3 concentrations than NP1 (both p<0.0001). Concentrations of 129 
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3-epi-25(OH)D3 were lowest in non-pregnant women (5.1, 3.9-6.4 nmol/L). Both NP1 (7.6, 6.0-130 
9.2 nmol/L) and NP3 (7.5, 5.9-8.6 nmol/L) had higher levels of 3-epi-25(OH)D3 but this was not 131 
significant. Highest 3-epi-25(OH)D3 levels were observed with PET (8.8, 5.9-11.8 nmol/L), with 132 
significant differences compared to  non-pregnant (p<0.001), NP1 (p<0.05) and NP3 groups 133 
(p<0.05) (Figure 1D). In non-pregnant women serum 25(OH)D3 was strongly correlated with 134 
1,25(OH)2D3 (p=0.013), 24,25(OH)2D3 (p<0.0001) and 3-epi-25(OH)D3 (p=0.012), but similar 135 
correlations were not consistently observed in pregnancy (Supplemental Figure 1).  136 
 137 
Serum DBP, albumin and free/bioavailable 25(OH)D3  138 
Data in Figure 2A showed a trend towards increased serum DBP in NP1 and NP3 pregnancies 139 
relative to non-pregnant women, but there was no significant difference in DBP between NP3 140 
and PET. Serum albumin was significantly lower in NP3 and PET pregnancies relative to non-141 
pregnant women (p<0.001 and p<0.05 respectively) and NP1 pregnancies (p<0.001 and p<0.05 142 
respectively) (Figure 2B). DBP and albumin values, together with total serum 25(OH)D3 levels, 143 
were used to calculate bioavailable (Figure 2C), and free serum 25(OH)D3 (Figure 2D) but 144 
these showed no significant change across pregnancy or with PET. 145 
 146 
Ratios of DBP-bound 25(OH)D3 to total 25(OH)D3 were unaffected by pregnancy or PET 147 
(Supplemental Figure 2A). However, the suppression of serum albumin with pregnancy 148 
significantly decreased the ratio of ‘bioavailable’ 25(OH)D3 (25(OH)D3 bound to albumin but not 149 
DBP) to ‘total’ serum 25(OH)D3 across normal pregnancy and PET (Supplemental Figure 2B). 150 
In a similar fashion, elevation of DBP levels in pregnant women resulted in decrease ratios of  151 
‘free’ 25(OH)D3 to total 25(OH)D3, with this effect being more pronounced in PET pregnancies 152 
(Supplemental Figure 2C). 153 
 154 
Decreased placental tissue concentrations of 25(OH)D3 in PET pregnancies 155 
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In contrast to the placenta, 1,25(OH)2D3 was quantifiable in decidual tissue (17.6, 11.0–23.4 156 
pmol/mg protein), and this paralleled increased decidual concentrations of 25(OH)D3 (21.0, 157 
9.3–60.5 nmol/mg protein) relative to paired NP1 placentae (1.2, 0.7-2.2 nmol/mg protein, 158 
p<0.001) (Figure 3A). By contrast no difference in tissue levels of 24,25(OH)2D3 were observed 159 
between decidua (0.3, 0.2–0.4 nmol/mg) and placenta (0.2, 0.1–0.3 nmol/mg). Similarly, 160 
decidual concentrations of 3-epi-25(OH)D3 (0.1, 0.1–0.3 nmol/mg) were not significantly 161 
different to NP1 placental 3-epi-25(OH)D3 (0.2, 0.1–0.3 nmol/mg) (Figure 3A).  162 
 163 
In placenta tissue, concentrations of 25(OH)D3 increased significantly from NP1 (1.2, 0.7-2.2 164 
nmol/mg protein) to NP3 (5.0, 4.0-6.5 nmol/mg protein, p<0.0001), but this effect was not 165 
observed for PET placenta levels of 25(OH)D3 (2.5, 1.4-3.5 nmol/mg protein) which were 166 
significantly lower than NP3 values (p<0.01) (Figure 3B). Consistent with maternal serum data, 167 
placental 24,25(OH)2D3 values were highest for PET (0.4, 0.3–0.6 nmol/ mg) relative to NP3 168 
(0.3, 0.3–0.5 nmol/mg) and NP1 (0.2, 0.1-0.4 nmol/mg, p<0.01) (Figure 3B). Placental 3-epi-169 
25OHD3 values were also higher for PET (0.4, 0.3–0.7 nmol/mg) relative to both NP3 (0.3, 0.2–170 
0.4 nmol/mg, p<0.05) and NP1 pregnancies (0.2, 0.1–0.3 nmol/mg, p<0.001) (Figure 3B). 171 
Placental concentrations of 1,25(OH)2D3 were below the lower limit of quantification. In NP1 172 
(data not shown) and NP3 pregnancies (Figure 4A) placental concentrations of 25(OH)D3 173 
correlated with maternal serum total, DBP-bound, bioavailable and free 25(OH)D3. By contrast, 174 
placental concentrations of 25(OH)D3 in PET pregnancies showed no association with any form 175 
of maternal serum 25(OH)D3 (Figure 4B).   176 
 177 
Discussion 178 
PET is a pregnancy-specific hypertensive, multisystem syndrome which complicates up to 8% 179 
of pregnancies [25], and is associated with significantly increased maternal and perinatal 180 
mortality and morbidity [29]. Although pathogenesis is not fully understood, PET is characterised 181 
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by abnormal decidual maternal spiral artery remodelling by invading fetal extravillous 182 
trophoblast (EVT) cells. [30]. Importantly, this critical placentation process appears sensitive to 183 
local vitamin D metabolites within both decidua and placental tissues [9]. In contrast to previous 184 
reports describing decreased serum 25(OH)D3 in PET [13, 14, 31], vitamin D-deficiency was 185 
observed for most of the women in the current study, despite this being a predominantly white 186 
Caucasian cohort. This may be due to the smaller size and non-matched cohort used [14], or 187 
the fact that some studies quantified serum 25(OH)D3 using ELISA technology which cannot 188 
distinguish between 25(OH)D3 and 3-epi-25(OH)D3 and may therefore over-estimate serum 189 
vitamin D ‘status’ [13, 31].  Nevertheless, the over-arching conclusion from data presented here 190 
is that simple measurement of serum 25(OH)D3 provides a very limited perspective of vitamin D 191 
in pregnancy.  192 
 193 
Previous studies have reported PET-associated declines in serum 1,25(OH)2D3 [31, 32], similar 194 
to those reported in the current study. This may be due to decreased serum levels of insulin-like 195 
growth factor 1 [32], a stimulator of renal 1α-hydroxylase, or lower expression of 1α-hydroxylase 196 
in the placenta [33], but other PET studies have reported increased whole human placental 197 
tissue 1α-hydroxylase expression [34]. Data presented here suggest that metabolism of 198 
25(OH)D3 to 24,25(OH)2D3 may indirectly lower 1,25(OH)2D3 in PET. Enhanced ‘catabolism’ of 199 
25(OH)D3 to 24,25(OH)2D3 in PET may be due to increased placental (trophoblast) expression 200 
of the enzyme 24-hydroxylase [34], although the underlying basis for this remains unclear [35]. 201 
Alternative metabolism of vitamin D may also occur via epimerisation of 25(OH)D3. The 202 
resulting 3-epi-25(OH)D3 can be converted to 3-epi-1,25(OH)2D3, and then bind to VDR to 203 
activate target gene transcription [36]. However, 3-epi-1,25(OH)2D3 is a much less potent VDR 204 
agonist than 1,25(OH)2D3, suggesting that epimerisation of 25(OH)D3 acts to dial-down VDR 205 
activity by generating a less effective ligand for the receptor [37]. It is notable that 3-epi-206 
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25(OH)D3 concentrations were significantly higher in the PET cohort, so this metabolic pathway 207 
may also play a key role in the dysregulation of vitamin D function in PET.  208 
 209 
This is the first study to use paired placental, decidual and serum samples to assess the 210 
relationship between circulating and tissue-specific levels of vitamin D metabolites. The 211 
relatively high levels of 25(OH)D3 in decidua enabled quantification of 1,25(OH)2D3, but 212 
determinants of both decidual 25(OH)D3 and 1,25(OH)2D3 remain unclear (Supplemental 213 
Figure 2). The most likely determinant of decidual 1,25(OH)2D3 is local tissue expression of 1α-214 
hydroxylase. In unpublished studies we have shown that decidual 1α-hydroxylase mRNA 215 
correlates with mRNA for inflammatory cytokines such as interleukin-6 and interferon-γ, 216 
suggesting that immune activity could be a key driver of decidual 1,25(OH)2D3.  Less clear is 217 
what determines decidual levels of the substrate for 1α-hydroxylase, 25(OH)D3. It was 218 
interesting that neither maternal nor placental 25(OH)D3 showed any correlation with decidual 219 
25(OH)D3, despite the proximity of these tissues (Supplemental Figure 2), suggesting that the 220 
the decidua has an autonomously regulated vitamin D system.  221 
 222 
In contrast to the decidua, data for placental tissue support the general assumption that 223 
variations in circulating 25(OH)D3 are manifested by equivalent tissue changes in 25(OH)D3. In 224 
NP3, placental 25(OH)D3 was closely correlated with maternal 25(OH)D well beyond levels of 225 
sufficiency (>75 nmoL/L). This was not observed in placentas from PET pregnancies, 226 
irrespective of serum 25(OH)D3 concentration (Figure 4B). This may, in part, reflect 227 
dysregulation of tissue catabolism of 25(OH)D3, as placental 24,25(OH)2D3 was highest for 228 
PET. However, tissue 3-epi-25(OH)D3 was significantly lower in PET placentas, suggesting that 229 
this catabolic pathway does not contribute to suppression of 25(OH)D3 in the placenta.  230 
 231 
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In recent years there has been increasing interest in the potential role of serum DBP not only as 232 
a transporter of vitamin D metabolites, but also as a determinant of 25(OH)D3 tissue access 233 
either as unbound or ‘free’ 25(OH)D3, or through receptor-mediated uptake of DBP-bound 234 
25(OH)D3 [24]. In the current study variations in serum DBP and albumin across pregnancy 235 
(Figure 2) resulted in subtle changes in the relative proportions of bioavailable and free 236 
25(OH)D3 (Supplemental Figure 3). It has been recognised for many years that serum 237 
albumin decreases with pregnancy, due to increased maternal blood volume [38]. This may be 238 
exacerbated in PET, although the extent to which this occurs varies with disease severity [38]. 239 
Previous studies using 1st trimester serum did not demonstrate any significant variation in DBP 240 
or 25(OH)D3 between pregnancies that went on to normal term or PET delivery [39].  241 
For both NP1 and NP3, serum DBP correlated with placental DBP, but this was not observed in 242 
PET placentas, or NP1 decidua (Supplemental Figure 4A). PET may therefore involve  243 
dysregulated endocytic uptake of DBP via the membrane receptor megalin which is expressed 244 
in the placenta [40]. Although DBP uptake by the placenta appears to be dysregulated in PET, 245 
other data do not support a major role for DBP as a determinant of placental or decidual 246 
25(OH)D3. Firstly, placental DBP was higher in NP1 than NP3, whereas placental 25(OH)D3 247 
was higher in NP3 (Supplemental Figure 4A). Most importantly there was no correlation 248 
between placental or decidual DBP and the levels of 25(OH)D3 in these tissues for NP1 249 
(Supplemental Figure 4C and 4D) or NP3 (data not shown). Collectively these data suggest 250 
that the close association between maternal serum 25(OH)D3 and levels of this metabolite in 251 
placental tissue involves placental uptake of DBP, but other mechanisms determine the final 252 
tissue-specific concentrations of 25(OH)D3. Dysregulation of this process in PET may reflect 253 
aberrant spiral artery development and placental blood flow, both of which are associated with 254 
malplacentation and may alter DBP uptake and 25(OH)D3 metabolism. We have shown 255 
previously that 25(OH)D3 and 1,25(OH)2D3 promote matrix invasion by human trophoblastic 256 
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cells [9], and similarly demonstrated dysregulated placental vascularisation and elevated blood 257 
pressure in vitamin D-deficient pregnant mice [41]. Thus further studies are required to 258 
determine whether decreased placental 25(OH)D3 is a cause or consequence of PET.  259 
The validity of the monoclonal antibody to DBP used in the R&D assay employed in the current 260 
study has been subject to recent debate, specifically reported differential immunoreactivity 261 
against epitopes on major DBP isoforms [42, 43]. This potential limitation of the DBP assay is 262 
specifically relevant to black populations, and it is important to recognise that the cohort in the 263 
current study was predominantly white. Nevertheless, future studies will benefit from direct 264 
measurement method for ‘free’ 25(OH)D3 and using newly established assays [44].  265 
 266 
The over-arching conclusions from this study are: 1) that PET is characterised by changes in 267 
multiple vitamin D metabolic pathways, emphasising the limited information to be gained from 268 
measurement of maternal 25(OH)D3; 2) changes in maternal DBP and albumin do not appear 269 
to have a major impact on the bioavailability and placental/decidual accumulation of vitamin D; 270 
3) in normal healthy pregnancies, maternal serum 25(OH)D3 is closely correlated with placental 271 
25(OH)D3, underlining the potential benefits of vitamin D supplementation in pregnancy; 4) this 272 
effect is lost in PET pregnancies, and the potential impact of this on resulting offspring will be a 273 
target for future studies; 5) in contrast to the placenta, the decidua can synthesise detectable 274 
levels of 1,25(OH)2D3. However, the underlying mechanistic basis for regulation of this 275 
metabolism in the decidua is still unclear, and requires further investigation. An important 276 
limitation of the present study is the large inter-group variability in all vitamin D metabolites 277 
measured and most likely reflects the small sample size and non-matched study design. 278 
Validation of these findings in a high-powered, matched cohort study including pregnant women 279 
with PET versus normotensive pregnant and non-pregnant controls is required to inform any 280 
future vitamin D supplementation trial targeting correction of the vitamin D metabolome.  281 
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Legends to figures 1 
Figure 1. Serum vitamin D metabolites in pregnant and non-pregnant women. Serum 2 
concentrations of: A) 25-hydroxyvitamin D3 (25(OH)D3) nmol/L; B) 1,25-dihydroxyvitamin D3 3 
(1,25(OH)2D3) pmol/L; C) 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) nmol/L; D) 3-epi-4 
25(OH)D3 nmol/L. Samples groups were: non-pregnant women; healthy 1st trimester (NP1); 5 
healthy 3rd trimester (NP3); preeclampsia 3rd trimester (PET). Statistically significant variations 6 
are indicated, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 7 
 8 
Figure 2. DBP, albumin and 25(OH)D3 bioavailability in pregnant and non-pregnant 9 
women. Serum concentrations of: A) vitamin D binding protein (DBP) (µmol/L); B) albumin 10 
(µmol/L); C) DBP-bound 25-hydroxyvitamin D3 (25(OH)D3) (nmol/L); D) bioavailable 25(OH)D3; 11 
E) free 25(OH)D3. Samples groups were: non-pregnant women; healthy 1st trimester (NP1); 12 
healthy 3rd trimester (NP3); preeclampsia 3rd trimester (PET). Statistically significant variations 13 
are indicated, * p<0.05, ** p<0.01, *** p<0.001, **** p< 0.0001. 14 
 15 
Figure 3.  Placental and decidual tissue vitamin D metabolites in pregnant women.  16 
A) Comparison of decidual and placental  concentrations of 1,25-dihydroxyvitamin D3 17 
(1,25(OH)D3), 25-hydroxyvitamijn D3 (25(OH)D3), 24,25-dihydroxyvitamin D3 (24,25(OH)2D3), 18 
and 3-epi-25(OH)D3 in NP1 pregnancies. All nmol/mg decidual protein. B) Placental 19 
concentrations of 25(OH)D3, 24,25(OH)2D3, and 3-epi-25(OH)D3 in: healthy 1st trimester (NP1); 20 
healthy 3rd trimester (NP3); pre-eclampsia 3rd trimester (PET) pregnancies. All nmol/mg 21 
placental protein. Statistically significant variations are indicated, * p<0.05, ** p<0.01, *** 22 
p<0.001, **** p<0.0001. 23 
 24 
Figure 4. Effect of maternal serum 25-hydroyxvitamin D3 (25(OH)D3) on placental 25 
concentrations of 25(OH)D3. Serum concentrations of total, DBP-bound, bioavailable and free 26 
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25-hydroxyvitamin D3 (25(OH)D3) (nmol/L) were correlated with placental tissue concentrations 27 
of 25(OH)D3 (nmol/g placental tissue) in healthy 1st trimester (NP1), healthy 3rd trimester (NP3) 28 
and pre-eclampsia 3rd trimester (PET) samples. 29 
 30 
 31 
 32 
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● Activation of vitamin D is decreased and its catabolism increased in preeclampsia  
 
● Maternal and placental vitamin D are correlated but this does not occur with decidua 
 
● Placental accumulation of vitamin D is impaired in preeclampsia 
 
● Placental uptake of vitamin D binding protein is dysregulated in preeclampsia 
 
 
 
